Robaxin
(Methocarbamol)ApprovedSmall molecule
Robaxin is one of 29 small molecule programs targeting Ventral Hernia. It is currently in Approved.
3
Indications
9
Total Trials
3
Active Trials
28
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
18 competitors in Rib Fracture
#DrugCompanyPhaseTrials
1Journavx
Vertex PharmaceuticalsApproved
Naropin
FFresenius Kabi USA, LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Total Knee Replacement1 trial
4 more indications
Trial1 trial
Rib Fracture1 trial
Ventral Hernia1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ROBAXIN
NDA NDA011790
Jan 1, 1982
ROBAXIN
NDA NDA011011
Jul 30, 2025
ATMEKSI
NDA NDA219843
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methocarbamol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]